The breast cancer suppressor protein, BRCA1, is a ubiquitin ligase expressed in a wide range of tissues. However, inheritance of a single BRCA1 mutation significantly increases a woman's lifetime chance of developing tissue-specific cancers in the breast and ovaries. Recently, studies have suggested this tissue specificity may be linked to inhibition of estrogen receptor ␣ (ER␣) transcriptional activation by BRCA1. Here, we show that ER␣ is a putative substrate for the BRCA1/BARD1 ubiquitin ligase, suggesting a possible mechanism for regulation of ER␣ activity by BRCA1. Our results show ER␣ is predominantly monoubiquitinated in a reaction that involves interactions with both BRCA1 and BARD1. The regions of BRCA1/BARD1 necessary for ER␣ ubiquitination include the RING domains and at least 241 and 170 residues of BRCA1 and BARD1, respectively. Cancer-predisposing mutations in BRCA1 are observed to abrogate ER␣ ubiquitination. The identification of ER␣ as a putative BRCA1/BARD1 ubiquitination substrate reveals a potential link between the loss of BRCA1/BARD1 ligase activity and tissue-specific carcinoma.
The breast cancer suppressor protein, BRCA1, is a ubiquitin ligase expressed in a wide range of tissues. However, inheritance of a single BRCA1 mutation significantly increases a woman's lifetime chance of developing tissue-specific cancers in the breast and ovaries. Recently, studies have suggested this tissue specificity may be linked to inhibition of estrogen receptor ␣ (ER␣) transcriptional activation by BRCA1. Here, we show that ER␣ is a putative substrate for the BRCA1/BARD1 ubiquitin ligase, suggesting a possible mechanism for regulation of ER␣ activity by BRCA1. Our results show ER␣ is predominantly monoubiquitinated in a reaction that involves interactions with both BRCA1 and BARD1. The regions of BRCA1/BARD1 necessary for ER␣ ubiquitination include the RING domains and at least 241 and 170 residues of BRCA1 and BARD1, respectively. Cancer-predisposing mutations in BRCA1 are observed to abrogate ER␣ ubiquitination. The identification of ER␣ as a putative BRCA1/BARD1 ubiquitination substrate reveals a potential link between the loss of BRCA1/BARD1 ligase activity and tissue-specific carcinoma.
breast cancer ͉ ubiquitylation ͉ ubiquitination ͉ steroid hormone receptor T he breast cancer suppressor protein, BRCA1, is essential for early development and associated with a number of cellular processes including cell proliferation, cell cycle progression, apoptosis, and DNA repair/recombination. Inheritance of a single mutation in BRCA1 increases a woman's lifetime risk of developing breast cancer from 1 in 9 to greater than 1 in 2 (1) . Additionally, in sporadic nonfamilial cases of breast cancer, BRCA1 expression is significantly reduced, indicating loss of BRCA1 at the protein or mRNA level (2, 3) . Therefore, BRCA1 inactivation either through mutation or repression of gene expression is implicated in all forms of breast cancer development.
The only known enzymatic activity associated with BRCA1 is its activity as a ubiquitin protein ligase (4) . Attachment of ubiquitin to substrates is a versatile method of regulation involved in practically all aspects of cell biology. Substrate ubiquitination involves several steps and a well-known trio of enzymes called ubiquitin activating (E1), ubiquitin conjugating (E2), and ubiquitin ligase (E3). The E3 activity of BRCA1 has been localized to the N-terminal RING domain and depends on heterodimerization with the RING domain of BARD1 (5) . Importantly, all BRCA1 cancer-predisposing mutations within the RING domain are observed to eliminate the BRCA1/ BARD1 E3 activity both in vitro and in vivo (5) (6) (7) . This strongly suggests a link between the tumor suppressor function of BRCA1 and its E3 activity. The ultimate fate of a ubiquitinated substrate depends on both the number of ubiquitins linked in a chain and the ubiquitin chain topology (8) . BRCA1/BARD1 has been observed to monoubiquitinate proteins as well as build Lys-6-linked polyubiquitin chains. Lys-6-linked chains are recognized by the 26S proteasome for deubiquitination rather than degradation (9) , suggesting ubiquitination by BRCA1/BARD1 may signal for processes other than degradation. To understand the biological function of the BRCA1/BARD1 E3 ligase and the relationship to cancer development, specific BRCA1/BARD1 ubiquitination substrates must be identified.
The BRCA1/BARD1 putative ubiquitination substrates identified to date (histones, ␥-tubulin, RNA polymerase II, and CtIP) cannot explain the association of ubiquitously expressed BRCA1 with the development of tissue-specific breast and ovarian tumors (10) (11) (12) (13) (14) . Recently, however, BRCA1 has been shown to interact with and regulate estrogen receptor ␣ (ER␣) and progesterone receptor (PR) transcriptional activation (15) (16) (17) . Of the Ͼ50 proteins known to interact with BRCA1, only ER␣ and PR have expression profiles similar to BRCA1 mutationassociated tumors. ER␣ and PR are transcription factors whose activity is modulated by binding the hormones estrogen and progesterone, respectively. Hormone binding elicits a conformational change that enhances receptor dimerization and binding to hormone-responsive DNA elements located in the promoter region of target genes. Transcriptional activation is then promoted through recruitment of coregulators and transcriptional machinery. This results in estrogen and progesterone displaying tissue-selective actions through ER␣ and PR that are central in the growth, differentiation, and function of the breast and ovaries. Both clinical and experimental evidence indicates that endogenous exposure to female reproductive hormones is a central factor in the development of breast cancer (18, 19) . This suggests that regulation of ER␣ and PR transcriptional activation by BRCA1 could have significant implications in controlling breast tissue proliferation.
Modulation of ER␣ and PR functions by BRCA1 is a compelling explanation for the linkage between BRCA1 and tissuespecific cancers. The mechanism of this regulation, however, is largely unknown. Both mono-and polyubiquitinated forms of ER␣ have been observed in vivo (20, 21) , with ubiquitination occurring after transcription initiation and functioning to clear ER␣ from the promoter. The E3 responsible for ER␣ ubiquitination is unknown. In a recent study, proteasome-mediated degradation was found to regulate PR but not ER in mouse mammary gland tissue, with BRCA1/BARD1 implicated in the formation of polyubiquitin chains on PR (22) . Here, we show the ligand-binding domain (LBD) of ER␣ is predominantly monoubiquitinated by BRCA1/BARD1, suggesting a possible mechanism for regulation of ER␣ activity by BRCA1. The regions of BRCA1, BARD1, and ER␣-LBD necessary for ubiquitination are determined. In addition, the effects of BRCA1 cancerpredisposing mutations and the specificity of BRCA1/BARD1-mediated ER␣ ubiquitination are evaluated.
Results

ER␣ Is
Ubiquitinated by BRCA1/BARD1. The interacting regions of BRCA1 and ER␣ were previously localized to ER␣-LBD and BRCA1 302 (BRCA1 residues 1-302) (16) . Similar notation is used throughout the text to indicate the length of BRCA1 and BARD1 constructs, with all BARD1 constructs beginning at Met 26. Consistent with BRCA1 302 and ER␣-LBD interacting, we observe that BRCA1 304 /BARD1 327 ubiquitinates estrogenbound ER␣-LBD, when reconstituted in vitro with other ubiquitination enzymes. The BRCA1/BARD1 E3 ligase predominantly monoubiquitinates ER␣-LBD as determined by Western blotting against both a V5-epitope on ER␣-LBD and a T7-epitope on ubiquitin [ Fig. 1A and supporting information (SI) Fig. 6 ]. Monoubiquitination regulates diverse processes ranging from membrane transport to transcriptional regulation; whereas polyubiquitination is known to signal proteins for events such as degradation and DNA repair (23) . Therefore, monoubiquitination of ER␣-LBD by BRCA1/BARD1 may suggest BRCA1/ BARD1 regulates ER␣ activity by using processes other than degradation, consistent with a recent report of constant ER levels in mouse mammary gland tissue (22) . Alternatively, other factors not present in the reconstituted system may be required for the formation of polyubiquitin chains on ER␣. Importantly, removal of the V5-epitope on ER␣-LBD before and after ubiquitination shows the V5-epitope is neither causal for ER␣ ubiquitination nor is the epitope ubiquitinated (SI Fig. 6 ).
Regions of BRCA1/BARD1 and ER␣ Necessary for Ubiquitination.
ER␣-LBD ubiquitination requires regions beyond the RING domains of BRCA1/BARD1. BRCA1 112 /BARD1 140 , which contains the minimal RING domains and is an active E3 for building free ubiquitin chains (7), is not sufficient for ER␣-LBD ubiquitination (Fig. 1 A) . This suggests specific interactions between BRCA1/BARD1 beyond the RING domains and ER␣-LBD are required for ubiquitin transfer. The effects of both BRCA1 and BARD1 on ER␣-LBD ubiquitination were determined by using varying lengths of BRCA1 and BARD1. BRCA1 304 /BARD1 140 and BRCA1 112 /BARD1 327 both ubiquitinate ER␣-LBD, with only BRCA1 112 /BARD1 327 showing slightly reduced ER␣ ubiquitination relative to BRCA1 304 /BARD1 327 ( Fig. 1 A) . This suggests ER␣-LBD interacts with regions of both BRCA1 and BARD1 beyond the RING domains for ubiquitination. Because the RING domains of BRCA1/BARD1 contain the E2 binding site (7), these residues are necessary, although not sufficient, for ER␣ ubiquitination. BRCA1/BARD1 E3 activity depends on heterodimerization (5), therefore the ability of BRCA1 or BARD1 alone to ubiquitinate ER␣ cannot be determined.
To determine the region of BRCA1 necessary for ER␣-LBD ubiquitination, BRCA1 length was varied while keeping BARD1 confined to the RING domain. Shortening BRCA1 to 241 residues results in slightly decreased ER␣-LBD ubiquitination, however, decreasing BRCA1 to 177 residues or less greatly reduces or eliminates ER␣ ubiquitination ( Fig. 1 A and B) . This suggests BRCA1 residues between 177 and 241 along with the N-terminal RING domain are required for ER␣ ubiquitination. In addition, BRCA1 residues between 241 and 258 affect the level of ER␣ ubiquitination (Fig. 1B) . Notably, BRCA1 constructs ending between amino acids 177 and 241 degraded rapidly during purification and were not assayed for ER␣ ubiquitination.
The region of BARD1 necessary for ER␣ ubiquitination was determined by decreasing the length of BARD1 while keeping BRCA1 confined to the RING domain. ER␣ ubiquitination mediated through BARD1 interactions require that BARD1 is longer than 170 residues, because truncating BARD1 to residues 26-170 significantly decreases ER␣-LBD ubiquitination (Fig.  1C) . Combined, these results indicate BRCA1/BARD1-mediated ER␣ ubiquitination requires regions of BRCA1 between residues 1-241 and regions of BARD1 extending beyond residue 170.
BRCA1/BARD1 ubiquitinates both agonist-and antagonistbound ER␣-LBD ( Fig. 2A) . Estrogen binds to ER␣-LBD and acts as an agonist to promote ER␣ transcriptional activity, whereas tamoxifen acts as an antagonist in breast tissue (24) . Estrogen and tamoxifen bind the same site in ER␣, however, agonists and antagonists induce a different conformation of helix 12 at the LBD C terminus (25, 26) . This conformational change either allows or inhibits binding of coregulators to the ER␣ coactivator-binding region (Fig. 2B) , which is formed by a shallow hydrophobic groove containing residues from helices 3, 4, and 5 (26) . Ubiquitination assays with either estrogen-or tamoxifen-bound ER␣-LBD show both liganded states are ubiquitinated by BRCA1/BARD1 (Fig. 2 A) . Apo ER␣-LBD was not amenable to purification and therefore not investigated for in vitro ubiquitination. There are two possible explanations for the ubiquitination of both estrogen-and tamoxifen-bound ER␣-LBD. First, BRCA1/BARD1 interacts with a different surface of ER␣ than the coactivator-binding region, which is affected by the movement of helix 12 in estrogen-and tamoxifen-bound states. Alternatively, crystal structures of ligand-bound ER␣ indicate that the position of helix 12 is highly flexible, with one structure even showing helix 12 extended away from the main protein core (27) . Therefore, the flexible nature of helix 12 may allow BRCA1/BARD1 to interact with the ER␣ coactivatorbinding region and ubiquitinate ER␣ in both liganded states.
The region of ER␣-LBD that interacts with BRCA1/BARD1 for ubiquitination was investigated by scanning mutagenesis, focusing on the ER␣ coactivator-binding region. Five single mutations in the ER␣ coactivator-binding region (I358A, Q375A, V376A, L378A, and L379A) were assessed for ubiquitination by BRCA1/BARD1. Of these mutations, both I358A and Q375A slightly weaken BRCA1/BARD1-mediated ER␣ ubiquitination (data not shown). Double mutation of I358A/Q375A, however, significantly decreases ER␣-LBD ubiquitination by BRCA1/BARD1 (Fig. 2 A) , suggesting mutation of I358 and Q375 in the ER␣ coactivator-binding region decreases interactions with BRCA1/BARD1 and therefore decreases ubiquitination. An interaction between BRCA1/BARD1 and the ER␣ coactivator-binding region is consistent with previous studies showing peptides containing the ER␣-LBD coactivator-binding region can interact with BRCA1 302 (28) . ER␣-I358A/Q375A is native-like, as determined by near-and far-UV CD and a thermal melt similar to WT (data not shown).
Effect of BRCA1 Cancer-Predisposing Mutations on ER␣ Ubiquitination. Inheritance of a single BRCA1 mutant allele significantly increases a woman's lifetime risk of developing breast cancer (1). Therefore, effects of BRCA1 RING domain cancer-predisposing mutations on ER␣ ubiquitination were determined. Both BRCA1-C61G and -C64G are mutations observed in breast cancer patients and have previously been shown to eliminate substrateindependent BRCA1/BARD1 ligase activity (6, 7) . Consistent with this, ER␣-LBD is not ubiquitinated by either mutant protein (Fig.  3) , indicating that these BRCA1 cancer-predisposing mutations disrupt BRCA1/BARD1-mediated ER␣ ubiquitination.
Mutation of Ile 26 to Ala (I26A) in BRCA1 also abrogates ER␣-LBD ubiquitination. BRCA1-I26A is a designed mutant protein that is structurally identical to WT BRCA1 and heterodimerizes with BARD1. However, BRCA1-I26A cannot interact with E2 enzymes and therefore is dominant negative for BRCA1 ligase activity (7). BRCA1-I26A/BARD1 fails to ubiquitinate ER␣-LBD (Fig. 3) , indicating that ER␣ ubiquitination depends on the E3 ligase activity of BRCA1/BARD1. This is further supported by a lack of ER␣ ubiquitination in the absence of BRCA1/BARD1 (data not shown).
Substrate Specificity in Vitro. BRCA1/BARD1 displays substrate specificity for ER␣-LBD ubiquitination. Substrate specificity was assessed by using the ER␣ DNA-binding domain (ER␣-DBD) as a BRCA1/BARD1 substrate. Eight of the Ϸ80 residues in ER␣-DBD are Lys, however, in vitro, after 60 min, ER␣-DBD is only weakly ubiquitinated by BRCA1 304 /BARD1 327 , whereas significant levels of ER␣-LBD are ubiquitinated after 20 min (Fig. 4B) . This suggests that, in vitro, the BRCA1/BARD1 ligase shows specificity for the LBD over the DBD. BRCA1/BARD1 substrate specificity was investigated further by competing ER␣-LBD ubiquitination with DBD over a 1:1 to 50:1 molar ratio of DBD:LBD (Fig. 4A) . ER␣-LBD ubiquitination is unchanged at all DBD concentrations investigated, indicating BRCA1/ BARD1 specifically ubiquitinates ER␣-LBD even with a 50-fold molar excess of DBD present. Therefore, in vitro, BRCA1/ BARD1 displays substrate specificity and specific interactions are required for ER␣-LBD ubiquitination, rather than a simple diffusion-based mechanism.
Substrate specificity was further assessed by the ability of BRCA1/BARD1 to ubiquitinate hen egg white lysozyme, which has previously been used as a generic ubiquitination substrate for E3s (11) . Lysozyme is not ubiquitinated by BRCA1/BARD1 in our reconstituted system, confirming that specific interactions between the substrate and BRCA1/BARD1 are required for ubiquitination. Additionally, competition of ER␣-LBD ubiquitination with a 50-fold molar excess of lysozyme does not affect ER␣-LBD ubiquitination (SI Fig. 7) . Furthermore, although the RING domains of BRCA1/BARD1 are an active E3 ligase, they do not ubiquitinate ER␣ (Fig. 1 A) , implying E3 specificity for ER␣ ubiquitination. Simply having an active E3 ligase is not sufficient for ER␣ ubiquitination; rather ubiquitination requires specific interactions between BRCA1/BARD1 sequences past the RINGs and ER␣.
The specificity of BRCA1/BARD1-dependent ER␣ ubiquitination was also investigated by using two E2 conjugating enzymes, UbcH5c and UbcH7. UbcH5c and UbcH7 are Ϸ60% similar in protein sequences and nearly identical in structure. Both UbcH5c and UbcH7 can be charged with ubiquitin and 3) ubiquitinates ER␣-LBD; BRCA1 cancer-predisposing mutations, C61G (lanes 4 -6) and C64G (lanes 7-9), do not. ER␣-LBD is not ubiquitinated by the BRCA1 mutant, I26A (lanes 10 -12), which maintains E3 structural integrity but disrupts E2 binding (7).
interact with the same region of BRCA1/BARD1 (7). However, only UbcH5c builds polyubiquitin chains with BRCA1/BARD1 (5, 7). Similarly, only UbcH5c transfers ubiquitin to ER␣ (Fig.  4C ), indicating that ER␣ ubiquitination by BRCA1/BARD1 requires interaction between BRCA1 and a specific E2.
Lys 302 in ER␣ Is Ubiquitinated by BRCA1/BARD1. The site on ER␣ ubiquitinated by BRCA1/BARD1 was identified by trypsin digestion and mass spectrometry. Trypsin proteolysis of a ubiquitinated protein creates a distinct signature peptide at the ubiquitination site. This peptide contains a two-residue Gly-Gly remnant from the C terminus of ubiquitin that is covalently attached to the substrate Lys, resulting in a mass shift of 114.1 Da (29) . The precise site of ubiquitin modification is determined by HPLC and mass spectrometry. To identify the ER␣ residue ubiquitinated by BRCA1/ BARD1, reactions were analyzed Ϯ ATP. No ubiquitination will occur in the absence of ATP, so peptides observed only with ATP arise from ubiquitination. A ubiquitination site in ER␣ was mapped to K302 in both ϩ 2 and ϩ 3 charge state mass spectra ( Fig. 5A and  SI Fig. 8 ). The peptide sequence and localization of the diglycine ubiquitin remnant on K302 are validated by a SEQUEST (30) XCorr of 3.5 and y-and b-ion series fragments observed for the majority of the sequence (Fig. 5A ). In addition, the extracted ion chromatogram for this peptide shows a significant increase in the presence of ATP, further confirming that the peptide is ubiquitinated (Fig. 5B) . Trypsin does not cleave at a modified Lys; therefore, ubiquitinated Lys residues will have a missed tryptic cleavage site. As determined from Western blots, Ϸ20% of the ER␣ in solution is ubiquitinated, therefore, the corresponding unmodified peptide should have a decrease in intensity between reactions in the absence and presence of ATP. Indeed, the intensity of the extracted ion chromatogram for the peptide containing unmodified K302 decreases Ϸ20% in the presence of ATP, further confirming K302 as a site of ubiquitin attachment on ER␣ (Fig. 5C ). Mutagenesis was attempted to confirm ubiquitination of ER␣ K302 by BRCA1/BARD1. Mutation of K302 to Ala still results in ER␣-LBD ubiquitination by BRCA1/BARD1. Therefore, each of the 13 ER␣-LBD Lys residues was individually mutated to either Ala or Arg; in addition a K302A/K303A double mutation was investigated. BRCA1/BARD1 ubiquitinates each of the ER␣-LBD Lys mutants (data not shown), indicating that if the primary ubiquitinated Lys is mutated, another nearby Lys can be ubiquiti- 3) and ER␣-DBD (lanes 4 -6). The molecular weight of ubiquitinated ER␣-DBD is marked (OE). ER␣-DBD is not bound to DNA. (C) E2 specificity of BRCA1/BARD1-mediated ER␣-LBD ubiquitination. ER␣-LBD is ubiquitinated by BRCA 304/BARD1140 in the presence of UbcH5c (lanes 1-3) but not UbcH7 (lanes 4 -6). All Western blots were analyzed by using anti-V5 against V5-ER␣-LBD and V5-ER␣-DBD. nated. This phenomenon is consistent with other E3s and ubiquitination substrates in vitro (31) . Importantly, identification of ubiquitin on K302 does not preclude the possibility that a different Lys on a separate ER␣ is ubiquitinated but not detected by mass spectrometry. ER␣-LBD-K302A/K303A is, however, still specifically ubiquitinated over the DBD (SI Fig. 9 ), suggesting that the observed specificity for ER␣-LBD is not a result of having a Lys adjacent to the N-terminal tag. Finally, ER␣ is predominantly monoubiquitinated by BRCA1/BARD1, indicating that ubiquitination of a single Lys prevents other Lys residues within the same molecule from being ubiquitinated. The biological consequence of ubiquitination, the most famous of which is targeting substrates with polyubiquitin chains to the proteasome for degradation, depends on both the number of ubiquitins added to a substrate and ubiquitin chain topology (8) . In contrast, substrate monoubiquitination regulates diverse proteins including histones, endocytic machinery, and transcription factors (23) . In our study, we observed predominant monoubiquitination of ER␣-LBD by BRCA1/BARD1 (Fig. 1 A) , consistent with previous observations of in vitro monoubiquitination of histones and ␥-tubulin by BRCA1/BARD1 (10) (11) (12) . Monoubiquitination of transcriptional activators has been suggested to be principal in regulating activator activity (32) , suggesting ER␣ monoubiquitination may be functionally relevant. Alternatively, additional factors not present in the reconstituted system may be necessary for chain elongation on BRCA1/BARD1 substrates.
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Discussion
The putative region of ER␣ ubiquitinated by BRCA1/BARD1 is implicated in regulating ER␣ transcriptional activity. ER␣-LBD is ubiquitinated by BRCA1/BARD1 at K302 as determined by mass spectrometry (Fig. 5) . It is likely that BRCA1/BARD1 also ubiquitinates the adjacent residue K303, as ubiquitination enzymes do not display sufficient fidelity to ubiquitinate a particular Lys preferentially over an adjacent Lys. Ubiquitinated K303 was likely not detected by mass spectrometry because a missed trypsin cleavage at K303 would generate a large peptide with Ն4ϩ charge state within the measured m/z range. We did not consider peptides Ն4ϩ in our analysis because peptides of this length are underrepresented in analyses using low-resolution tandem mass spectrometry and generally are ignored in proteomics experiments (33, 34) . K302 and K303 are located in the hinge that connects the ER␣-DBD and -LBD. The hinge region has 43% identity from Homo sapiens to Xenopus laevis, whereas ER␣-DBD and -LBD have 99% and 82% identity over the same species, respectively. Intriguingly, ER␣ hinge residues between K302 and S305, immediately before the start of the LBD, are Ϸ85% conserved between Homo sapiens and Xenopus laevis. The higher conservation of K302-S305 relative to the rest of the hinge suggests this region may be functionally important. Indeed, several modifications have been observed at these residues: sumoylation of K302 and K303, acetylation of K303, and phosphorylation of S305 (35, 36) . In addition, a K303R mutation has been observed in as many as 34% of premalignant breast tumors, whereas WT ER␣ is expressed in normal tissue. The K303R mutation renders breast cells hypersensitive for proliferation in response to low doses of estrogen (37) . The hypersensitivity has been suggested to result from a lack of acetylation at K303 and increased phosphorylation at S305 (36) . However, inability of K303R to be ubiquitinated could also contribute to proliferation hypersensitivity.
BRCA1/BARD1-mediated ER␣ ubiquitination may represent the regulatory mechanism for repression of ER␣ transcriptional activation by BRCA1. This inhibition has been suggested to occur from an interaction between BRCA1 302 and ER␣-LBD (16, 28) . These studies found that the BRCA1 RING domain (residues 1-67) is not required for the observed interaction with ER␣, and that the cancer-predisposing mutation, C61G, in full-length BRCA1, does not disrupt the BRCA1-ER␣ interaction. However, in apparent contradiction to these observations, BRCA1-C61G fails to repress ER␣ transcriptional activity (16) . ER␣-LBD ubiquitination by BRCA1/BARD1 requires the BRCA1/BARD1 RING domains and at least 241 residues of BRCA1 (Fig. 1) . However, BRCA1-C61G disrupts ER␣-LBD ubiquitination (Fig. 3) . The observation that BRCA1-C61G interacts with ER␣-LBD but does not repress ER␣ activity, together with the loss of ER␣ ubiquitination by BRCA1-C61G suggests ubiquitination of ER␣ by BRCA1/BARD1 could regulate ER␣ transcriptional activity.
Central to understanding the biological function of the BRCA1/BARD1 ligase and its relationship to cancer is the identification of BRCA1/BARD1 ubiquitination substrates. Several putative BRCA1/BARD1 ubiquitination substrates have been identified including histones, ␥-tubulin, RNA polymerase II, and CtIP (10) (11) (12) (13) (14) . Although each has advanced our understanding of the BRCA1/BARD1 E3 ligase, none provide a clear correlation between ubiquitously expressed BRCA1 and the development of tissue-specific cancers. Here, we show ER␣ is a putative substrate for the BRCA1/BARD1 E3 ligase, providing a compelling link between the loss of BRCA1 ligase activity and BRCA1-associated tissue-specific tumorigenesis. Exposure to estrogen is known to be a central factor in the development of breast cancer (19) ; therefore, regulation of ER␣ activity by BRCA1, possibly through ER␣ ubiquitination, could have significant implications in controlling breast tissue proliferation. Further studies investigating the biological role of BRCA1/ BARD1-mediated ER␣ ubiquitination will surely reveal additional insights regarding the impact of these events on breast and ovarian cell proliferation.
Materials and Methods
Plasmids. Plasmids for expression of BRCA1, BARD1, UbcH5c, UbcH7, ubiquitin, and Uba1 were derived from those described previously (7, 38) . ER␣-LBD (residues 302-552) and ER␣-DBD (residues 180-262) were cloned into pET151D (Invitrogen, Carlsbad, CA). Point mutations were introduced by QuikChange (Stratagene, La Jolla, CA) and confirmed by DNA sequencing (University of Washington Biochemistry Sequencing).
Protein Expression and Purification. All proteins were expressed in Escherichia coli as described (38) . Briefly, pCOT7-His 6 -FLAG-BRCA1 and pET28N-BARD1 of specified lengths were cotransformed and grown in BL21star(DE3). BRCA1/BARD1 was purified by Ni 2ϩ -affinity and size exclusion chromatography (Superdex 75 or Superdex 200) in 25 mM sodium phosphate, 150 mM NaCl, pH 7.0. BRCA1/BARD1 was used within 12 h of purification. pET28N-UbcH5c was transformed and grown in BL21(DE3) cells and purified by cation exchange (SP Sepharose) eluted with a 0-0.5 M NaCl gradient in 30 mM Mes and 1 mM EDTA (pH 6.0). UbcH5c fractions were purified further
